TGFB1 and neoplasm: However, the anti-tumor effect of TGF-β1 is often bypassed by cancer cells, which may display a wide range of mutations in key points of the TGF-β1 signaling pathway, such as those regarding TRβ2 or Smad2/Smad4 genes [42,43,44].